Clinical trials: Glioma Surgery

Glioma, Recurrence

Vorasidenib Expanded Access Program

• Approved For Marketing
• Age: 12 years and older
• Expanded access

This is an expanded access program to provide vorasidenib for treatment of patients 12 years or older with IDH1- or IDH2-mutated glioma.

Conditions

Glioma, Recurrence, Disease Attributes, Pathologic Processes

Trial name

NCT05592743

Testing

Vorasidenib

Sponsor

Servier